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Heterozygosis for CYP21A2 Mutation Considered as 
21-Hydroxylase Defi ciency in Neonatal Screening
ABSTRACT
Steroid 21-hydroxylase defi ciency (21-OHD) accounts for more than 90% of 
congenital adrenal hyperplasia. CAH newborn screening, in general, is based 
on 17-hydroxyprogesterone dosage (17-OHP), however it is complicated by 
the fact that healthy preterm infants have high levels of 17-OHP resulting in 
false positive cases. We report on molecular features of a boy born pre-term 
(GA = 30 weeks; weight = 1,390 g) with elevated levels of 17-OHP (91.2 nmol/L, 
normal < 40) upon neonatal screening who was treated as having CAH up to 
the age of 8 months. He was brought to us for molecular diagnosis. Medica-
tion was gradually suspended and serum 17-OHP dosages mantained nor-
mal. The p.V281L mutation was found in compound heterozygous status with 
a group of nucleotide alterations located at the 3` end intron 4 and 5’ end exon 
5 corresponding to the splice site acceptor region. Molecular studies contin-
ued in order to exclude the possibility of a nonclassical 21-OHD form. The 
group of three nucleotide changes was demonstrated to be a normal variant 
since they failed to interfere with the normal splicing process upon minigene 
studies. (Arq Bras Endocrinol Metab 2008; 52/8:1388-1392)
Keywords: Neonatal screening; CYP21A2 mutations; Minigenes; 21-hydroxy-
lase defi ciency
RESUMO
Heterozigose para Mutação no Gene CYP21A2 Considerada como Defi ciência 
de 21-Hidroxilase na Triagem Neonatal.
A defi ciência de 21-hidroxilase (21-OHD) é uma doença autossômica recessi-
va que contribui com mais de 90% dos casos de hiperplasia congênita da 
adrenal. O teste de dosagem de 17-hidroxiprogesterona (17-OHP) por radio-
imunoensaio em amostras de sangue colhidas em papel de fi ltro tem sido o 
método mais usado nos programas de triagem neonatal. No entanto, essa 
triagem pode apresentar alto número de falso-positivos pelo fato de os re-
cém-nascidos prematuros apresentarem dosagens mais elevadas deste es-
teróide. Apresentamos aqui os estudos moleculares de uma criança, sexo 
masculino, nascida pré-termo (IG = 30 sem; peso = 1.390 g) que apresentava 
valores elevados de 17-OHP sérica (91,2 nmol/L, normal < 40) na triagem neo-
natal e que foi tratada como portadora da forma clássica da 21-OHD até a 
idade de 8 meses quando nos foi encaminhada para diagnóstico molecular. A 
terapia foi, então, gradativamente descontinuada, sendo que as concentra-
ções séricas de 17-OHP se mantiveram normais. A mutação p.V281L foi en-
contrada em heterozigose composta com um grupo de alterações no terminal 
3’ do íntron 4 e no terminal 5’ do éxon 5 correspondendo à região do sítio 
aceptor de splicing. A análise do gene CYP21A2 prosseguiu para se excluir a 
possibilidade de a criança ser afetada com a forma não-clássica de 21-OHD. 
Pela análise de minigene fi cou demonstrado que o grupo de três trocas nu-
cleotídicas não afeta o processo normal de transcrição. Concluindo, a criança 
é apenas heterozigota da mutação p.V281L sem necessidade de tratamento. 
(Arq Bras Endocrinol Metab 2008; 52/8:1388-1392)
Descritores: Triagem neonatal; Mutações CYP21A2; Minigenes; Defi ciência 
de 21-hidroxilase
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Steroid 21-hydroxylase defi ciency (21-OHD; OMIM +201910) is an autossomal disorder that accounts for 
more than 90% of congenital adrenal hyperplasia (CAH) 
(1,2). Impaired 21-hydroxylase activity results in de-
creased cortisol and aldosterone levels. Frequently, the 
classical 21-OHD causes ambiguous external genitalia at 
birth in females, precocious puberty in males, and ac-
celeration of somatic growth in both sexes (1,2). If the 
level of the enzyme impairment is higher than 99%, min-
eralocorticoid synthesis is severely affected leading to 
salt-wasting crisis. Therefore, clinical symptoms may in-
clude failure to thrive, vomiting, hyperkalemia, hypona-
tremia, dehydration, metabolic acidosis (1,2). The 
nonclassical form (NC) is characterized by late-onset 
manifestation and results from a mild defi ciency of the 
enzyme. The excess of androgens presents different ef-
fects in nonclassical patients at any phase of postnatal 
development as pseudoprecocious puberty, hirsutism, 
acne, short stature, and decreased fertility (2).
21-OHD is caused by mutations on CYP21A2 
gene that in general are derived from its adjacent 
pseudogene on chromosome 6p21. Either carriers for 
CYP21A2 mutations or NC patients with homozygous 
CYP21A2 mutations present an overlapping range for 
responses of 17-OHP levels upon ACTH test that var-
ies, from values of 13 nmol/L up to 30 nmol/L (3). 
The higher value is generally considered as the lower 
limit for the diagnosis of the NC form (4, 5). However, 
this value is normally established before the identifi ca-
tion of mutations in the CYP21A2 gene. 
There is a high number of different techniques for 
diagnosing 21-OHD, but most CAH newborn screen-
ing is based on 17-hydroxyprogesterone radioimmu-
noassay on dried blood on fi lter paper (6-8). Nationwide 
and regional CAH screening programs have been in-
troduced in several countries (7, 9, 10) including in a 
few regions in Brazil (11, 12).
In the present study, we report the molecular featu-
res of a child that presented elevated level of 17-OHP 
in the neonatal screening, which was normalized within 
few months of age. The search for CYP21A2 mutations 
indicated compound heterozygosis for p.V281L muta-
tion and a group of three nucleotide alterations located 
at the 3`-end intron 4 and 5`-end exon 5 correspon-
ding to the splice site acceptor region. Molecular stu-
dies continued to exclude the possibility of this boy to 
develop a NC form of 21-OHD later. This group of 
alteration was demonstrated to be a normal variant sin-
ce it failed to interfere with the normal splicing process 
upon minigene studies. 
SUBJECTS AND METHODS
Clinical report
A Brazilian Caucasian male from non-consanguineous 
parents was born pre-term (GA = 30 weeks; weight = 
1,390 g; height = 40 cm), after an in vitro fertilization 
triplet pregnancy. Upon 21-hydroxylase defi ciency ne-
onatal screening he presented high levels of 17-hydro-
xyprogesterone (17-OHP) (91.2 nmol/L, normal < 
40). At the age of 27 days confi rmatory test was perfor-
med and 17-OHP serum value was 73 nmol/L (nor-
mal 3,5 to 122). The child has never had dehydration 
or vomiting episodes. Also, failure to thrive was never 
observed. He was treated with hydrocortisone and was 
referred to our outpatient clinics when he was 8 mon-
ths old for molecular studies because the parents were 
interested in pre-natal diagnosis in future pregnancies. 
The treatment was gradually suspended during four 
months in order to confi rm the diagnosis. At the age of 
22 months he was asymptomatic and his 17-OHP se-
rum level was 2.2 nmol/L (normal 0.2 to 4.6). Normal 
growing and normal 17-OHP levels did not indicate 
the classical form of 21-hydroxylase. 
DNA extraction and analysis of the 
CYP21A2 gene
This study was reviewed and approved by the appro-
priate Ethics Committee from Faculdade de Ciências 
Médicas at Universidade Estadual de Campinas (Uni-
camp, Campinas-SP, Brasil) and informed consent was 
obtained from the parents. 
Genomic DNA samples from the child and his pa-
rents were obtained from peripheral blood by Proteina-
se K digestion and phenol/chloroform extraction 
following standard techniques (13). CY21A2 large 
gene conversions and 30-kb deletions were screened by 
Southern-blot (14). The eight most frequent pseudo-
gene-derived mutations were investigated by ASO-
PCR (15). For sequencing experiments, CYP21A2 
gene was amplifi ed in two fragments, 5’UTR-exon 6 
and exon 6-3’UTR, using specifi c CYP21A2 primers 
(15). The amplifi ed fragments were purifi ed with Wi-
zard SV Gel and PCR Clean-UP System (Promega) 
and directly sequenced with Big Dye Terminator Cycle 
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Sequencing Kit V3.1 Ready Reaction (ABI PRISM/PE 
Biosystems, Foster City, CA, USA) using the internal 
primers as previously described (16). Purifi ed PCR pro-
ducts were sequenced in both sense and antisense 
orientations using ABI PRISM 3700 Automated DNA 
Sequencer according to the manufacturer’s recommen-
dations (ABI PRISM/PE Biosystems, Foster City, CA, 
USA). Nucleotide and amino acid numbering followed 
the published sequence by Higashi et al. (17) (NCBI 
#M12792). 
Minigene construction, transfection 
and cDNA analysis
A minigene with a fragment spanning from exon 2 to 
exon 6 was constructed. After the fi rst amplifi cation to 
select CYP21A2 gene, a nested-PCR was performed 
to construct the minigene with the following primers: 
Exon 2 sense-Xba I 5´- CCA GAT GTC TAG ATG 
ATG AAC TCC AAG -3´ and Exon 6 antisense-Bam 
HI 5´- GTG GAT CCG AGG GGA GGC CGT -3´. 
The minigene amplifi cation product was purifi ed with 
Wizard SV Gel and PCR Clean-UP System (Promega, 
Madison, WI, USA) and digested with Xba I and 
BamH I restriction enzymes. The digested fragment 
was ligated into a BamH I/Xba I opened pSVL vector 
(Pharmacia, Piscataway, NJ, USA). These construc-
tions were transformed into E. coli DH5α competent 
cells. Clones with the correct insert size (1,110 bp) 
were sequenced to verify their identity. Recombinant 
plasmids were transfected in COS-7 cells. Approxima-
tely 1 x 106 cells were plated in each 10 cm diameter 
tissue culture dish containing 8 mL DMEM medium 
(Invitrogen Carlsbad, CA, USA) supplemented with 
10% fetal calf serum (FCS) and antibiotics. After 24 
hours, COS-7 cell cultures were transfected with 10 
µg of the construction using Lipofectamine 2000 (In-
vitrogen). Transfected cells were collected 24 hours 
after transfection and total RNA was isolated by use of 
RNeasy mini kit (Qiagen, Hilden, Germany), follo-
wed by DNase I (Invitrogen) digestion. First-strand 
synthesis was performed using 1 µL of Improm II re-
verse transcriptase (Promega) according to the 
manufacturer’s recommendations. The cDNA was 
amplifi ed by PCR using the internal primers Ex3Ns – 
Ex6Na (15). PCR products were fractioned and isola-
ted on a 1.5% agarose gel and the products were 
directly sequenced as described above with appropria-
te primers. 
RESULTS
A child with high 17-OHP serum levels in the neonatal 
screening was referred to molecular investigation on 
CYP21A2 gene. Southern blot analysis from family 
members revealed neither 30-kb deletions nor gene 
conversions (data not shown). However, upon screen-
ing for eight pseudogene-derived mutations by ASO-
PCR the heterozygosis for p.V281L mutation was 
observed. Segregation analysis performed by screening 
parents’ DNA showed that the father was a carrier for 
p.V281L (Figure 1A). The mother’s inherited allele, 
however, did not show any pseudogene-derived muta-
tion. In order to characterize this allele, CYP21A2 di-
rect sequencing analysis of the entire gene was 
performed. The group of alterations g.1104A>C + 
g.1111C>T + g.1121C>G, the fi rst two located at 
IVS4-15A>C and IVS4-8C>T, respectively, and the 
third in the fi rst codon of exon 5 leading to the putative 
missense p.D183E was identifi ed (Figure 1B). 
As those nucleotide changes, now named IVS4-Ex5, 
were located within intron 4/exon 5 junction sequence 
and could interfere with the normal acceptor splice site, 
they were investigated on their infl uence upon the for-
mation of the correct CYP21A2 transcript using mini-
Figure 1. (A) ASO-PCR results for p.V281L. Amplifi ed fragments were separated on a 1% agarose gel. Left - the V281 normal 
primer; right – L281 mutant primer. F - father; M - mother; S - child; NC - normal control; MC - mutant control; HC- heterozygous 
control. The 1-kb Plus DNA ladder (Invitrogen) was used as marker. (B) DNA sequencing data of the male child showing part of 
intron 4 - exon 5 boundary region. The arrows indicate the nucleotide changes.
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gene constructions. The cDNAs resulted from the 
transcription of minigene containing CYP21A2 exons 3 
to 6 did not show any sequence difference between the 
normal control and the variant constructs (Figure 2). 
DISCUSSION
A male child presenting high levels of 17-OHP in the 
neonatal screening was conducted to molecular investi-
gation for CYP21A2 mutations.
CYP21A2 gene was screened for 30-kb deletion, 
large gene conversion and pseudogene-derived muta-
tions. The paternal inherited allele showed p.V281L. 
This mutation is pseudogene-derived and it is known 
to present a residual enzymatic activity of 20-50% (18, 
19). It is considered the most common Caucasian mu-
tation among cases of NC form of 21-OHD (20). The 
maternal allele presented three nucleotide changes, 
named IVS4-Ex5. These changes are also pseudogene-
derived but had never been described in the active 
CYP21A2 gene, except one report on the D183E mu-
tation in exon 5 (21). As no other sequence variations 
were observed in the maternal allele the IVS4-Ex5 nu-
cleotide change was considered as a result of a rare mi-
croconversion mutational event.
The exon 5 g.1121C>G causing the mutation p.
D183E had been studied before and did not affect the 
normal enzymatic activity, therefore was considered a 
polymorphism in CYP21A2 (19). However, the IVS4-
Ex5 nucleotide changes together were not investigated. 
Due to their location in the acceptor splice site region, 
they could interfere with the normal splicing process. 
Minigene in vitro experiments demonstrated that the 
recognition of the intron 4 acceptor splice site by the 
spliceosome occurred in both wild-type and mutant se-
quences. Therefore, neither p.D183E reduces enzy-
matic activity nor IVs4-Ex5 nucleotide changes alter 
normal transcription indicating a normal variant for 
the allele.
Elevated 17-OHP blood level is normally used as 
an indicator of CAH. In general, the technique of 
analyzing 17-OHP in neonatal screenings is radioim-
munoassay in fi lter-paper blood samples (6, 7). It has 
been discussed by several authors that this procedure 
generate a high rate of positive results attributable to 
physiological reasons and to cross-reactions with steroi-
ds other than 17-OHP, especially in preterm neonates 
(9,10). In addition, Bachega et al. (5) studied obligate 
heterozygote parents of patients with 21-OHD and 
they observed that 11 of 19 p.V281L carriers presented 
elevated ACTH-stimulated 17-OHP levels. Therefore 
we consider that this study illustrate such technical ar-
tifact where a p.V281L carrier newborn was considered 
as having 21-hydroxylase defi ciency and treated. Con-
cluding, the child described here cannot be considered 
affected with 21-OHD, although a rare allelic variant 
had been identifi ed in compound heterozygosis with 
p.V281L. 
Figura 2. Eletropherogram showing part of the cDNA sequence formed by exon 2 to exon 6. (A) wild-type minigene se-
quence; (B) sequence of minigene containing the IVS4-Ex5 nucleotide changes. The grey box denote the GAC> GAG trans-
version in codon 183 (p.D183E). Arrows indicate the exon 4 - exon 5 junction.
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In summary, the molecular study presented here 
contributed to defi ne the normal phenotype of a boy 
considered as 21-OHD in neonatal screening. Therefo-
re, this case illustrates the importance of molecular bio-
logy as feasible tools to confi rm presumed altered 
neonatal screening results. Furthermore, this report 
provided new insights concerning the function of pseu-
dogene-derived alterations in intron 4 / exon 5 accep-
tor splice site region. Knowledge about the functional 
effects of alterations improves a correct genotype-phe-
notype correlation. The molecular investigation poin-
ted out this case as a heterozygous carrier directing 
clinical management. 
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